Cargando…

Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study

Detalles Bibliográficos
Autores principales:	Shacham-Shmueli, Einat, Itay, Amit, Margalit, Ofer, Berger, Raanan, Halperin, Sharon, Jurkowicz, Menucha, Levin, Einav G., Levy, Itzchak, Olmer, Liraz, Regev-Yochay, Gili, Lustig, Yaniv, Rahav, Galia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616568/ https://www.ncbi.nlm.nih.gov/pubmed/34840027 http://dx.doi.org/10.1016/j.ejca.2021.10.019

Ejemplares similares

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study
por: Shmueli, Einat S., et al.
Publicado: (2021)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
por: Levy, Itzchak, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
por: Shmueli, Einat Shacham, et al.
Publicado: (2022)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
por: Lustig, Yaniv, et al.
Publicado: (2021)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season
por: Moss, Stephen, et al.
Publicado: (2023)

Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
por: Schwartz, Anat, et al.
Publicado: (2021)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders
por: Magen, Hila, et al.
Publicado: (2023)

A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
por: Joseph, Gili, et al.
Publicado: (2023)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
por: Amit, Sharon, et al.
Publicado: (2021)

Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
por: Nir, Omer, et al.
Publicado: (2022)

Missed opportunities for earlier diagnosis of HIV in patients who presented with advanced HIV disease: a retrospective cohort study
por: Levy, Itzchak, et al.
Publicado: (2016)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study
por: Layan, Maylis, et al.
Publicado: (2022)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
por: Lipsitch, Marc, et al.
Publicado: (2021)

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Benjamini, Ohad, et al.
Publicado: (2021)

The Sheba Medical Center healthcare workers' children's school: can we open schools safely?
por: Kriger, Or, et al.
Publicado: (2021)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer
por: Halpern, Naama, et al.
Publicado: (2023)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
por: Tadmor, Tamar, et al.
Publicado: (2021)

CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine
por: Amir, Gabriel, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
por: Brosh-Nissimov, Tal, et al.
Publicado: (2021)

A Typical Hospital-Acquired Methicillin-Resistant Staphylococcus aureus Clone Is Widespread in the Community in the Gaza Strip
por: Biber, Asaf, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d3hcid2pbeaojusb16dab49uuu